Mark Lappe’s Insider Buying Signals Confidence in Inhibrx’s Future Growth
CEO Mark Lappe buys 2.5 m Inhibrx shares after an 8.7% drop, showing strong insider confidence in a clinical‑stage drug pipeline poised for a rebound.
3 minutes to read
INHIBRX BIOSCIENCES INC
CEO Lappe Buys 3,324 Shares of INHIBRX – Insider Confidence Boosts Biotech Stock
CEO Lappe’s insider buying signals confidence in INHIBRX BIOSCIENCES, offering investors a steady, trust‑based stake amid volatile biotech markets.
3 minutes to read
Insider Surge: Douglas & Execs Buy 10k Inhibrx Options, Signaling 25% Upside
Insiders buy Inhibrx options, signaling confidence and a potential 25% upside—discover how this could boost the stock’s near‑term value.
4 minutes to read
Insider Buying Signals Confidence: 5,000 Shares Bought at $100 Boost Biopharma Valuation
Insider buying fuels confidence in a biotech firm’s value‑based strategy, adding $500K to equity and backing clinical, manufacturing, and AI growth.
4 minutes to read
Insider Selling Trend at Inhibrx Biosciences Signals Strategic Portfolio Shift, Not a Price Drop
Insightful review of Inhibrx Biosciences insider selling: why the trust’s 500‑share drops matter for investors and what the stock’s next move could be.
3 minutes to read
Insider Sale at INHIBRX Amid Strong Phase 2 Head‑and‑Neck Results: What It Means for Investors
Insider sale at InhibRx after Phase 2 head‑and‑neck success: 1,000 shares off a 0.5% stake, selling near $115 while execs buy, hinting at bullish pipeline.
3 minutes to read